



Explore what's possible with innovative
research tools

Discover the difference>



IL-10 as a Th2 Cytokine: Differences Between Mice and Humans

Mahima T. Rasquinha, Meghna Sur, Ninaad Lasrado and Jay Reddy

This information is current as
of October 18, 2021.

J Immunol 2021; 207:2205-2215; ;

doi: 10.4049/jimmunol.2100565

<http://www.jimmunol.org/content/207/9/2205>

References This article **cites 175 articles**, 55 of which you can access for free at:
<http://www.jimmunol.org/content/207/9/2205.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2021 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



IL-10 as a Th2 Cytokine: Differences Between Mice and Humans

Mahima T. Rasquinha,¹ Meghna Sur,¹ Ninaad Lasrado,¹ and Jay Reddy

The discovery of IL-10 more than 30 years ago marked the beginning of our understanding of how cytokines regulate immune responses, based on cross-regulation between Th1 and Th2 cytokines. Although multiple cell types were shown to produce IL-10, its identity as a Th2 cytokine remained strong because it was rigidly associated with Th2 clones in mice, whereas both Th1 and Th2 clones could secrete IL-10 in humans. However, as new Th1/Th2 cell functionalities emerged, anti-inflammatory action of IL-10 gained more attention than its inhibitory effect on Th1 cells, which may occur as an indirect consequence of suppression of APCs. This notion is also supported by the discovery of regulatory T cells, whose suppressor functions involve the mediation of IL-10, among other molecules. From this perspective, we discuss the functionalities of IL-10 by highlighting important differences between mice and humans with an emphasis on the Th1 and Th2 paradigm. *The Journal of Immunology*, 2021, 207: 2205–2215.

The paradigm of Th1 and Th2 cytokines has been one of the major landmarks in immunology since the discipline's inception in 1986 (1). The idea of cytokines secreted by Th1 and Th2 clones with distinct functions, as well as their cross-regulation, offered an excellent framework for understanding the pathogenesis of infections caused by a broad spectrum of microbes. For example, IFN- γ -producing Th1 cells are critical for eliminating intracellular pathogens via cell-mediated immunity (2). In contrast, B cell-stimulating factor 1 (now called IL-4) produced by Th2 cells is critical for Ab production needed to eliminate extracellular pathogens. Furthermore, the discovery that cytokine synthesis inhibitory factor (now called IL-10) in Th2 clones was a key molecule in inhibiting cytokine production by Th1 clones led to the phenomenon of cross-regulation between Th1 and Th2 subsets (3, 4). Although this paradigm is still relevant today, the discovery of additional subsets and the growing list of cytokines, combined with the use of modern molecular tools, has made us realize the

complexity of cytokine networks and the need to reinterpret the literature from time to time.

Cytokines are classified as families of ILs, IFNs, TNFs, growth factors, and chemokines based on their cellular sources, receptor elements, biological function, sequence homology, and common structural motifs. The IL-10 cytokine family consists of nine members categorized into three groups: IL-10 (stand-alone, group I); IL-19, IL-20, IL-22, IL-24, and IL-26 (IL-20 subfamily, group II); and IL-28A, IL-28B, and IL-29 (group III) (5, 6). The immunomodulatory effects of IL-10 have been extensively studied in various mouse models, which may have translational significance in humans. However, a certain degree of confusion continued to exist regarding the functional identities of IL-10 in these two species. For example, IL-10 was considered a Th2 cytokine in mice (3), whereas both Th1 and Th2 cells were known to secrete IL-10 in humans (7, 8). In this review, by accepting the limitation that it is difficult to make a head-to-head comparison between mice and humans for every known property of IL-10, we have made efforts to identify major differences between the two species regarding the properties and functions of IL-10 with an emphasis on its relationship to Th1 and Th2 subsets. Such a comparison may be helpful to better understand the role of IL-10 in infections and to refine therapeutic strategies involving IL-10. Their salient features are also discussed in this review. To illustrate the significance of IL-10 in health and disease, advancements made on the biology of IL-10 and its clinical applications are highlighted in Fig. 1. However, for a more comprehensive understanding of IL-10 family cytokines, readers are encouraged to consult excellent reviews published on this topic (9–11).

Biology of IL-10

After the functionality of IL-10 was identified as an inhibitory molecule of cytokine synthesis (1), cDNA clones encoding mouse and human IL-10 (hIL-10) were generated in 1990 and 1991, respectively (12, 13). In the following year, IL-10 genes were characterized in both species (Fig. 1); the IL-10 gene in mice consists of five exons, spans 5.1 kb, and is located on

School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE

¹These authors contributed equally.

ORCID: 0000-0003-0923-4869 (M.T.R.); 0000-0001-6762-2654 (N.L.); 0000-0003-4082-9254 (J.R.).

Received for publication June 17, 2021. Accepted for publication August 10, 2021.

This work was supported by the American Heart Association (Grant 18TPA34170206), the Department of Health and Human Services/National Institutes of Health (Grant 5R21AI142281), and the University of Nebraska–Lincoln Institutional funds.

M.T.R., M.S., and N.L. collected the literature, synthesized the information, created figures, and wrote the manuscript. J.R. assisted M.T.R., M.S., and N.L. in all the above activities.

Address correspondence and reprint requests to Prof. Jay Reddy, Room 202, Building VBS, Fair Street, East campus loop, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, NE 68583. E-mail address: nreddy2@unl.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: Breg, regulatory B cell; COVID-19, coronavirus disease 2019; DC, dendritic cell; hIL-10, human IL-10; IBD, inflammatory bowel disease; KO, knockout; mL-10, murine IL-10; PEG-IL-10, pegylated form of IL-10; SARS CoV-2, severe acute respiratory syndrome coronavirus 2; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism; STAT, signal transducing and activator of transcription; T-bet, T-box transcription factor TBX21; TF, transcription factor; Th, follicular T helper cell; Treg, regulatory T cell.

Copyright © 2021 by The American Association of Immunologists, Inc. 0022-1767/21/\$37.50




FIGURE 1. Major advancements made on the biology of IL-10 and its clinical applications. CSIF, cytokine synthesis inhibition factor. Created with bioRender.com.

chromosome 1E4, whereas the human gene spans ~ 4.7 kb and is located on chromosome 1q21-32 (14). The IL-10 protein comprises 160 aa that form a noncovalently linked homodimer of two interpenetrating α -helical bundles similar to IFN- γ , with a 73% identity between humans and mice (15). Recently, by linking IL-10 monomer subunits in a head-to-tail fashion with a flexible linker, murine IL-10 (mIL-10) has been engineered to form a dimer that showed enhanced biological activity and improved stability of IL-10 protein (16). Similarly, hIL-10 has been engineered to create a monomer that can still bind to the IL-10R and retain its biological activity, albeit with ~ 60 -fold less affinity and ~ 10 -fold lower specific activity than the IL-10 protein (17). Furthermore, synthetic peptides derived from the protein sequence of hIL-10 appear to mimic specific properties of IL-10, such as downregulation of expression of MHC class I in APCs and inhibition of IFN- γ -mediated induction of TAP1/TAP2 in vitro (18). Because these mimics were shown to bind IL-10R, they may have therapeutic benefits.

The IL-10R, a member of the IFN receptor family, comprises two chains, IL-10R1 and IL-10R2, the homodimers of which combine to form heterodimers (19). Of these two components, the specificity of IL-10 binding is defined by IL-10R1, whereas IL-10R2 is a component of other cytokines, namely IL-22, IL-26, IL-29, IL-28A, and IL-28B (6). Although mIL-10R1 binds to both mIL-10 and hIL-10, hIL-10R1 binds only to hIL-10 but not to mIL-10 (20). Furthermore, IL-10R1, although low in density, is expressed by most hematopoietic cells (21). Non-hematopoietic cells can also express IL-10R1 but not constitutively, and immune stimuli such as LPS can upregulate IL-10R1 expression (21, 22). In contrast, IL-10R2 is expressed constitutively (23). Furthermore, upregulation of IL-10R1 was found to be sufficient to activate the expression of IL-10R2 (24). Notably, the affinity of IL-10 to IL-10R1 is higher than its affinity to IL-10R2 (25). While IL-10R1 is indispensable for binding to IL-10, IL-10R2 does not bind to IL-10 directly (19). Instead, IL-10R2 is responsible for signaling events involving the participation of Janus kinase 1/tyrosine kinase 2/signal transducing and activator of transcription (STAT) 3, although STAT1 and STAT5 can also be involved (26). Nonetheless, the finding that loss of IL-10R2 leads to loss of responsiveness to IL-10 implies that activation through both receptor complexes may be critical for IL-10 to mediate complete functional activation (27). Additionally, homologs of IL-10 have been discovered in (and favor the survival of) viruses such as EBV, poxvirus, and CMV (28–30). Although the binding affinity of viral IL-10 with hIL-10R is ~ 1000 -fold lower than the binding of native hIL-10,

viruses can establish persistent/latent infection in the host by enhancing hIL-10 production (31, 32). These observations suggest that the IL-10R system is finely regulated to respond to IL-10, depending on the context, raising questions about the sources and functionalities of IL-10 in health and disease.

Cellular sources of IL-10

Historically, the inclusion of IL-10 in the Th1 and Th2 paradigm identified IL-10 as a T cell cytokine. In fact, 4 y after its discovery, IL-10 was reviewed as a cytokine with multiple sources, with an expression pattern resembling that of IL-6 (33). However, the inclusion of IL-10 in the Th2 subset was held for a long time, based on the concept of cross-regulation between Th1 and Th2 cells that offered a valuable framework for understanding the outcomes of infections. For example, in mouse models of leishmaniasis where the cutaneous form is associated with IFN- γ -secretion from Th1 cells in C57BL/6 mice, Th2 cytokines dominated the visceral form by inhibiting IFN- γ -producing CD4⁺T cells in BALB/c mice (34). Although the concept of Th1–Th2 cross-regulation is still valid, several factors might have contributed to the exclusion of IL-10 as specific to the Th2 subset, as described below.

1) IFN- γ produced by Th1 cells is critical in eliminating intracellular pathogens that can also influence the production of Abs [IgG2a in mice (35) and IgG1 (36) in humans]. Molecularly, IFN- γ suppresses the activation of STAT3 by shifting STAT activation from STAT3 to STAT1 (37), but the reverse is not true because the signaling molecules of IL-10 have not been known to suppress the signaling events of IFN- γ . Conversely, IL-4 produced by Th2 cells is needed for IgG1 and IgE production, whereas IL-5 can promote the formation of plasma cells and is a well-known growth factor of eosinophils in both mice and humans (38, 39). IL-13 could influence IgE secretion and facilitate barrier immunity by mucus production in epithelial cells that promotes gastrointestinal motility (40, 41). Thus, if the definition of Th2 cytokines promotes the expulsion of extracellular pathogens, such as helminths, then the combination of IL-4, IL-5, and IL-13 fulfills the requirement. In this scenario, IL-10 can forcibly be included as a Th2 cytokine, as IL-10 can enhance the survival of B cells in the germinal center of the spleen and stimulate the synthesis of IgA and IgG (42, 43). However, IL-10 also plays a role in downregulating IgE production (44). Such effects can be expected from any cytokine because of their pleiotropic, redundant, and synergistic effects, as long as the responding cells express relevant cytokine

receptors. This argument can be made because of an elegant study involving conditional knockout (KO) mice, in which IL-10R was deleted specifically in B cells (45). In this system, Ab production was surprisingly increased, leading to the proposition that the IL-10R pathway may negatively regulate Ab production in response to microbial infections.

2) The production of IL-10 is not limited to Th2 cells alone, especially in humans (33). To identify cellular sources of IL-10 with certainty, IL-10^{GFP} (VeRT-X) reporter mice were created, in which B cells of lymphoid origin and myeloid cells of the blood and liver were found to be the major producers of IL-10 (46). Similar observations were also made in 10BiT mice (47). However, through the creation of a more sensitive IL-10- β -lactamase reporter mouse, major sources of IL-10 were found to be F4/80⁺ macrophages in melanoma and CD11b⁺Ly-6G⁺ neutrophils during infection, suggesting that non-T cells may be the major producers of IL-10 (48). A recent report demonstrated that B cells from dominant negative IL-10R-expressing mice, in which IL-10 signaling is specifically blocked in T cells, produced lower amounts of Abs than B cells from wild-type mice in the presence of CCR6⁺IL-10eGFP⁺T cells but produced similar levels of Abs in the presence of Th17 cells (49). Importantly, by using reporter knock-in tiger mice, in which GFP was integrated into the IL-10 locus, it was demonstrated that strong IL-10 expression occurred in intraepithelial lymphocytes in the small intestine and colonic lamina propria lymphocytes (50). Furthermore, by using a double-knock-in reporter mouse that expresses IL-10 and forkhead box P3 simultaneously, a distinct population of renal regulatory T cells (Tregs) was found to be the source of IL-10 (51).

3) Molecularly, IL-10 expression involves transcription factors (TFs) cMaf, GATA3, E4 promoter-binding protein 4, STAT3, STAT4, and Jun independently of the expression pattern of well-known TFs of Th1 and Th2 subsets (52, 53). For example, T-box transcription factor TBX21 (T-bet), and GATA3, respectively, promote Th1 and Th2 responses, and these TFs cross-regulate each other in both mice and humans (54, 55). By this definition, IL-10 should be downregulated by T-bet, but this is not the case; instead, T-bet promotes IL-10 secretion (56). Similar effects have been noted with the RAR-related orphan receptor γ T (57). It may be that the TFs needed for IL-10 production could be expressed in multiple Th subsets. For example, Th17, Th22, and T cytotoxic 1 cells can produce IL-10 in humans (58–60), but limited data are available in mice regarding IL-10 secretion in these subsets. Thus, it is possible that promiscuous expression of TFs, combined with potential functional plasticity of T cells responding to multiple cytokines in the microenvironment, may restrict the expression of IL-10 to any given cell type.

4) In some experimental infections in mice, such as *Toxoplasma gondii* (61) and cutaneous form of *Leishmania major* infection (62), Th1 cells were identified as the major producers of IL-10, whereas in visceral form of *L. major* infection, Th2 cells were reported as the dominant producers (63). Regardless of sources (Th1 or Th2 cells), IL-10 is still a key molecule to prevent immune pathology (61–63). Conversely, regulatory B cells (Bregs) were identified as a major source of IL-10 in chronic schistosomiasis (64), whereas B cell-derived IL-10 suppressed Th1/Th17 responses in *Pneumocystis murine* infection (65). IL-10 produced by Bregs has also been critical for Th2 cell development in *L. major* infection (66). Recent reports also suggest that IL-10 produced by plasmablasts and not splenic B

cells in the draining lymph nodes is essential for the recovery process in the mouse model of experimental autoimmune encephalomyelitis (67). From studies in 10BiT reporter mice with persistent lymphocytic choriomeningitis virus infections, follicular T helper cells (Tfh) producing IL-10 were critical for promoting Ab response (68). In contrast, IL-10 secreted by tonsillar follicular T cells in humans suppressed the class switching of B cells to IgE (69). Likewise, monocyte-derived IL-10 can suppress Th2 polarization to control allergic reactions in the nasal mucosa of mice, and peritoneal macrophages were found to be the major source of IL-10 in mice infected with *Mycobacterium bovis* or *Escherichia coli* (70, 71). Thus, IL-10 production by diverse cell types may be functionally different, that may vary by stimuli.

Overall, IL-10 appears to be produced by many types of immune cells (Fig. 2). For simplicity, we have categorized these into innate immune cells, including eosinophils, monocytes, macrophages, dendritic cells (DCs), NK cells, NKT cells, innate lymphoid cells, mast cells, and $\gamma\delta$ T cells. Likewise, all adaptive immune cells (CD4⁺T cells, CD8⁺T cells, and B cells) can produce IL-10 (33). Additionally, various subsets possessing regulatory functions (Tregs, regulatory type 1 cells, regulatory innate lymphoid cells, Bregs, and Th3 cells) can produce IL-10 (66, 72–75). Notably, however, an unexpected phenotype has been observed with murine alveolar macrophages. Unlike humans (76), murine alveolar macrophages do not produce IL-10, even upon stimulation with LPS, but they retain their capacity to produce TNF- α (77). This observation has important implications for studying the pathogenesis of infectious and noninfectious triggers of lung disease because in the absence of anti-inflammatory effects of IL-10, the macrophage response may be skewed toward inflammatory cytokines that may not be translationally relevant to humans. Similarly, human neutrophils appear not to secrete IL-10 in response to molecules associated with inflammation, such as LPS, serum amyloid A-1 protein (78, 79). However, Tregs treated with LPS can stimulate neutrophils to produce IL-10 (80). These observations may also have implications for immunotherapies. Nevertheless, IL-10 can also be produced by nonimmune cells in both mice and humans that include mesenchymal stem cells, epithelial cells, and tumor cells (81–86). In mice, hepatic stellate cells can produce IL-10 to potentially overcome the effects of inflammatory cytokines (87, 88), but comparable studies are lacking in humans. Likewise, an unusual property is seen in a specific subset of taste cell receptors in mice, which secrete IL-10 to maintain the structural integrity of the peripheral gustatory system (89). Although such isolated observations may have translational significance, a deeper understanding is critical. For example, loss of taste has been identified as one symptom of coronavirus disease 2019 (COVID-19), and severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) may infect taste buds (90). By establishing a positive correlation between SARS CoV-2 infection of taste cells and IL-10 production, it may be possible to use blunt tongue scrapings from patients as a noninvasive modality to evaluate IL-10 as a prognostic marker. Furthermore, severely affected COVID-19 patients experiencing a cytokine storm can have elevated levels of serum IL-10 in addition to various inflammatory cytokines (91, 92). Reports also suggest that detection of IL-10 can be used as a biomarker of COVID-19 (91, 93). It appears that IL-10 may have a pathogenic role by enhancing the production of




FIGURE 2. Major sources of IL-10 and its responses, common to both mice and humans. Various immune and nonimmune cells, as indicated in the top panel, are known to produce IL-10 in mice and humans. Additionally, viruses also carry the homolog of IL-10. Regardless of cellular sources, IL-10 can act only on cells expressing the IL-10R consisting of both IL-10R1 and IL-10R2 components, as shown in the bottom panel. The table within the circle shows major functions of IL-10 mediated by the cell types shown for each function. Created with bioRender.com.

proinflammatory cytokines and activating CD8⁺T cells resulting potentially from hyporesponsiveness to IL-10 (93, 94). Taken together, IL-10 appears to be produced by both hematopoietic and nonhematopoietic cells, but the question arises whether such a broad spectrum of cell types can also respond to IL-10 to mediate its functions.

Responses to IL-10

Cytokines are bestowed with unique properties in that they can act on their producers (autocrine), influence neighbors (paracrine), and even work distantly (endocrine). Nonetheless, cytokines cannot cross the lipid bilayers of cells or diffuse into the cytoplasm; rather, cytokines must interact with their specific

receptors to enter cells. Such a restriction is advantageous to the host because only the receptor-bearing responding cells react to cytokines and produce defined outcomes. IL-10 is no exception to this rule. Unlike the vast array of producers of IL-10, the range of responders may be limited to a few cell types. These include innate (NK cells, DCs, monocytes, macrophages, and neutrophils) and adaptive immune cells (B cells, CD4⁺ T cells, and CD8⁺ T cells), in addition to mast cells (a component of both systems) and regulatory cells. Functionally, it is well established that IL-10 limits tissue damage by suppressing inflammatory responses of innate immune cells (monocytes/macrophages and DCs among others) (95). Furthermore, IL-10 is also known to suppress Ag-presentation functions, such as expression of MHC class II, and costimulatory molecules (e.g., B7 family) (Fig. 2) (96, 97), and effective cell-mediated immune responses continue to develop in healthy mice and humans, suggesting that the timing of IL-10 production may determine the outcomes of the immune responses. This can be best exemplified by the discovery that classically activated (M1) and alternatively activated (M2) macrophages mediate opposing functions; M2 cells producing IL-10 appear later in the innate response and suppress inflammatory cytokine production by M1 cells (98). Additionally, among various professional APCs, DCs are critical to present Ags to naive T cells, but they can partially escape from the inhibitory effects of IL-10 by downregulating the expression of IL-10R1 as shown in the human studies (99). Nevertheless, determination of disease phenotypes under the conditions of IL-10 deficiency or genetic defects in IL-10 and IL-10Rs has enabled us to better understand the immunoregulatory roles of IL-10 that we have summarized below with examples.

Mice. With the availability of genetically altered mice, it has become relatively easy to interpret the role of IL-10 in various infections. By using IL-10 KO mice or its receptors (IL-10R1 or IL-10R2), IL-10 was found both beneficial and detrimental in a wide range of microbial infections that include intracellular and extracellular bacteria, fungi, helminths, protozoa, and viruses (Fig. 3). For example, IL-10 KO mice infected with intracellular microbes, such as *Trypanosoma cruzi* and *Porphyromonas gingivalis*, were susceptible to infection with increased mortalities (100, 101). Similarly, in the case of classic extracellular pathogens such as helminths (*Litomosoides signodontis* and *Trichuris muris*), IL-10 KO mice failed to expel the parasites and had higher mortality rates (102, 103). Expectedly, the absence of IL-10 aggravated the disease phenotype by promoting the production of proinflammatory cytokines such as IFN- γ (100–103). These observations suggest that IL-10 may be beneficial for control of both intracellular and extracellular pathogens. However, in the case of a few other intracellular pathogens (e.g., *L. major*, *L. donovani*, and *M. tuberculosis*) and extracellular pathogens (e.g., *Streptococcus* spp.), IL-10 KO mice were found to be resistant (104–106), indicating that IL-10 can contribute to their disease pathogenesis. Although these findings suggest that immunomodulatory effects may vary by infection, it is possible that the cell type that produces IL-10 may dictate the disease outcome. For example, while both macrophages and T cells produce IL-10 during *L. major* infection (107, 108), conditional deletion of IL-10 in T cells exacerbated the disease (104). In contrast, no phenotypic changes were observed in mice having macrophage-specific IL-10 deletion (104). But, the beneficial effects of IL-10 have been well documented in most immune-mediated/autoimmune

diseases (Fig. 3), and the best-characterized example is enterocolitis (109).

Humans. Translationally, a similar picture has emerged for many of the disease conditions described above, in humans (Fig. 3). For example, IL-10 and IL-10R deficiencies were associated with ulcerative colitis, Crohn's disease, and celiac disease (110). Similarly, various single nucleotide polymorphisms (SNPs) have been identified in IL-10 or IL-10R genes, resulting in altered production of IL-10 or its functions (111, 112). These dysfunctions were associated with various microbial and immune-mediated diseases, including cancers, transplant rejections, and degenerative diseases (Fig. 3). The most common IL-10 polymorphisms are located in the promoter region upstream of the IL-10 gene that includes mainly rs1800871, rs1800872, and rs1800896 (113–116). Most SNPs are associated with an increased risk of infections/inflammation that could be influenced by ethnicity. In some cases, SNPs that increase susceptibility to one disease can decrease the risk for others. For example, SNPs rs1800871 (-819C/T) and rs1800872 (-592C/A) were associated with increased susceptibility to inflammatory bowel disease (IBD) in overall populations (117), but the same polymorphisms have decreased susceptibility to systemic lupus erythematosus (SLE) in Asian populations and hospital-based subgroups, respectively (118). However, it is to be noted that disease associations with SNPs in the IL-10 gene do not necessarily prove their causative role, and better interpretations can be made in studies involving large sample sizes, and ethnically diverse populations (116). Likewise, it is unknown whether the SNPs alter the production of IL-10 in different cell types. Although IL-10 polymorphisms may represent potential genetic biomarkers (113), it is possible that other cytokines can substitute the functions of IL-10. For example, STAT3-activating cytokines other than IL-10 (e.g., IL-21) can substitute the functions of IL-10 to induce differentiation of naive B cells to plasma cells (119, 120), suggesting that the immunomodulatory effects of IL-10 are complex in nature.

Role of IL-10 in inflammatory conditions. The anti-inflammatory effects of IL-10 have been proposed as a major mechanism for suppressing excessive immune responses, the lack of which may lead to the occurrence of autoimmune diseases, such as IBD, and multiple sclerosis, among others (109, 121). Conversely, IL-10 has been shown to play a pathogenic role in SLE by demonstrating that monocytes and B cells contributed to the overproduction of IL-10 in SLE patients and also in the mouse model (122). Recently, IL-10-producing CCR6⁺ T cells located in the extrafollicular areas distinguishable from Tfh cells were found to promote autoantibody production in an IL-10-dependent manner (123). Systemic accumulation of CCR6⁺IL-10⁺ T cells was also noted in mice with lupus-like disease (123). Indeed, treatment of lupus-prone NZB/W F1 mice with IL-10 Ab led to a reduction in the levels of serum anti-dsDNA IgG autoantibodies, in turn delaying the onset of disease, whereas administration of IL-10 accelerated autoimmunity (124). It may be that SLE patients may have a genetic predisposition to produce high levels of IL-10. Mechanistically, the ability of IL-10 to enhance survival and differentiation of B cells in conjunction with inhibition of apoptosis of autoreactive B cells may lead to the production of elevated levels of anti-dsDNA IgG titers in SLE patients (125). Similarly, by using the IL-10 transgenic mouse model involving the expression of IL-10 under the control of IL-2 promoter, IL-10 facilitated the




FIGURE 3. An overview of disease phenotypes (susceptible and resistant) observed in various mouse models (IL-10 KO, IL-10R KO, and IL-10 transgenic) and humans bearing SNPs in IL-10 or IL-10R genes. The left panels indicate the usefulness of IL-10 KO, IL-10R KO, and IL-10 transgenic mice to study disease phenotypes for various microbial infections (bacteria, fungi, viruses, protozoa, and helminths) and immune-mediated diseases (IMDs)/cancers in mice. Pink diamonds denote IL-10 protein. Similar studies were performed in humans bearing SNPs in IL-10 and IL-10R genes, and the major findings are indicated in the right panels. The numbers shown with the superscripts correspond to the reference SNP identifiers (rs) and are as follows: 1, rs1800896; 2, rs1800871; 3, rs1800872; 4, rs3024491; 5, rs1878672; 6, rs3024496; 7, rs1800870; 8, rs1800890; 9, rs2222202; 10, rs3024490; 11, rs6703630; 12, rs3024505; 13, rs1518111; and 14, -597 C/A. See Supplemental Table I for references.

development of experimental myasthenia gravis by increasing anti-acetylcholine receptor Abs corresponding to reduced IFN- γ production (126). These observations suggest that functions of IL-10 may vary by disease condition and Ag.

As for allergy, IL-10 plays a beneficial role as IL-10 KO mice develop enhanced allergic reactions with increased eosinophilic airway inflammation (127, 128). Various polymorphisms in the IL-10 gene were shown to be associated with severe asthma, and decreased levels of IL-10 were noted in the bronchoalveolar lavage fluid from asthmatic patients (129). Successful immune

therapies against allergy were also correlated with IL-10-secreting, Ag-specific T cells (125, 130). By using T cells deficient for IL-10R, it was demonstrated that IL-10 promotes Th2 cell death via granzyme B production (130). Although IL-10 produced by various cell types, including regulatory cells, can suppress type 2 responses and IgE production (131), the detrimental role of IL-10 cannot be discounted in allergic reactions. For example, IL-10 can promote the development of eosinophilia, airway hyper-responsiveness, mucus metaplasia and IL-5 production that culminate into proliferation and

activation of mast cells as shown in an experimental food allergy model (132). Whether such a dual action of IL-10 is allergen specific remains to be determined.

However, IL-10 has been shown to mediate a protective role in cardiovascular and metabolic disorders. For example, IL-10 can promote plaque healing by inhibiting IL-12 production in atherosclerosis patients (133). By using the chimeric low-density lipoprotein R KO and IL-10 KO models, it was demonstrated that leukocytes play a critical role in the prevention of atherosclerosis through modulation of the composition of cellular and collagen plaques (134). Additionally, IL-10 can suppress inflammation during postmyocardial infarction by promoting M2 polarization of macrophages that suppress inflammation and indirectly stimulate proliferative cardiac fibroblasts and collagen production (135). Likewise, IL-10 may act as a positive regulator of insulin sensitivity by influencing peripheral glucose metabolism, and cotreatment with IL-10 attenuates insulin resistance, as noted in an acute lipid infusion model in mice (136). This observation is consistent with reports showing the association of polymorphisms in IL-10 promoter with obesity and insulin resistance (137). Similarly, IL-10 produced by placental villous trophoblasts and maternal immune cells (Treg cells, uterine NK cells, and monocytes) has been proposed as one of the mechanisms for maintenance of fetal tolerance (138). IL-10 produced at the maternal–fetal interface during pregnancy may be critical for cross-talk between placental and decidual tissue (138). By acting on trophoblasts, IL-10 can regulate the expression of matrix metalloproteinase-9, which can cause hypertension, leading to preeclampsia (139, 140). Thus, IL-10 can be considered to be a pregnancy-compatible cytokine that favors fetal tolerance. But a question may arise whether the immune-suppressive properties of IL-10 can be exploited in clinical settings.

IL-10 in therapy

Accumulated literature suggests that IL-10 functions similarly in both mice and humans. For example, the primary immunodeficiency syndrome characterized by IBD resulting from the loss of IL-10 function due to a mutation in IL-10R is very similar to the enterocolitis phenotype noted in mice deficient for IL-10 or IL-10R (141, 142). These models have proved beneficial in understanding the mechanisms of colitis and Crohn's disease in which multihit hypotheses have been tested, leading to the development of therapies for IBD (143) (Fig. 1). The recombinant hIL-10 has been tested for treatment of Crohn's disease and acute pancreatitis (144). Similarly, the human recombinant fusion IL-10 has shown some degree of success against rheumatoid arthritis (145). However, these clinical applications of IL-10 to mitigate inflammatory conditions have yielded mixed successes that could have been influenced by other environmental factors, such as gut flora, nutrition, pollution, and toxins (146), pointing to a possibility that IL-10 could be beneficial in other disease conditions.

Tumors. It was believed for a long time that IL-10 produced by tumor cells in the tumor microenvironment was an escape mechanism because its production was proportional to the extent of metastasis, as demonstrated in melanoma patients (147). But the discovery that adenocarcinoma cells engineered to express mIL-10 in a mouse model led to regression of tumors was a contrasting finding (148). In this setting, tumor-

specific CD8⁺ T cells producing IL-10 can acquire memory phenotype, and their adoptive transfers into syngeneic recipients resulted in the rejection of tumors. Mechanistically, the terminally exhausted T cells exposed to IL-10–Fc fusion protein displayed better antitumor activity in solid tumors by undergoing metabolic reprogramming events (149). In combination with similar successes with mIL-10 as an antitumor agent in various mouse models, a pegylated form of IL-10 (PEG-IL-10) was created to prolong the half-life of IL-10 (150). Expectedly, PEG-IL-10 induced long-term CD8⁺ T cell memory, leading to shrinkage of immune-resistant tumors in various mouse models (150) and showed promise in regulating plasma cholesterol levels in hypercholesteremic cancer patients (151). Phase 1/1b clinical trials with PEG-IL-10 as monotherapy (152) or in combination with chemotherapy were also successful in other tumor settings in which IL-10 expression was correlated with infiltration of CD8⁺ T cells and survival rates (153). Therapeutic benefits of PEG-IL-10 have been ascribed to activation of CD8⁺ T cells, leading to upregulation of IFN- γ and granzyme B (152). Unfortunately, however, phase 2 and phase 3 clinical trials for metastatic pancreatic cancer and non-small cell lung carcinoma, respectively, with PEG-IL-10 combined with a chemotherapeutic drug mixture and a checkpoint inhibitor (programmed cell death protein 1 Abs [anti-PD-1]), did not show significant clinical benefits (Fig. 1) (154, 155). Nonetheless, a few other recent clinical trials for melanoma, renal cell carcinoma, and non-small cell lung carcinoma with PEG-IL-10 in conjunction with checkpoint inhibitors (anti-PD-1) appear promising (156). Although these outcomes reinforce the notion that antitumor drugs proven to be successful in mouse models may fail in human settings, the use of polytherapy as exemplified above can continue to be explored because universal recipes cannot be developed for all tumors. Such a notion may also be relevant for other disease conditions.

Virus infections. Consistent with the above theme, IL-10 may mediate protective functions in virus infections but can act as a double-edged sword. On the one hand, early production of IL-10 by innate immune cells may favor viral persistence and chronicity by impairing antiviral innate and CD8⁺ T cell responses leading to T cell exhaustion. On the other hand, late production of IL-10 can limit excessive inflammation through feedback regulatory mechanisms (157). Additionally, IL-10 can promote antiviral response by activating CD8⁺ T cells and NK cells (158, 159). In fact, in the murine coronavirus-induced encephalitis mouse model, highly activated CTLs in the brain have been shown to produce IL-10, and the cytolytic property was more pronounced in the IL-10⁺ CTLs than IL-10⁻ CTLs (160). Similarly, NK cells from chronically infected hepatitis C virus patients were shown to secrete IL-10 in the presence of melanoma cells. In these circumstances, preservation of cytolytic properties of CD8⁺ T cells and NK cells has been ascribed to IFN- γ , whose secretion remained intact (161). Although anti-inflammatory effects of IL-10 are well documented, the use of IL-10 in the face of a cytokine storm in disease conditions, such as COVID-19, may not be a viable option because excess production of IL-10 itself is considered a biomarker of severe disease that may also have a pathogenic role (91, 93).

Overall, clinical use of IL-10 still remains an enigma, with a major challenge being able to optimize therapeutic doses for each disease condition because lower doses may fail to elicit a response, whereas higher doses may lead to detrimental effects

(162, 163). For example, at higher doses of IL-10 in Crohn's disease and psoriatic patients, several unexpected effects such as fatigue, headache, anemia, and thrombocytopenia were observed in addition to the production of the proinflammatory cytokine IFN- γ (10). Other contributing factors include heterogeneity in the selection of patient populations, as might occur in Crohn's disease (10). Likewise, IL-10 therapy may be less effective in ameliorating the established disease (162), and clinical success may depend on the stage of disease for each condition. It is also possible that IL-10 alone may not be enough to suppress all proinflammatory reactions, and the immunosuppressive effects of IL-10 may be counterbalanced by its immune-stimulatory effects (162). Furthermore, the dual effects of IL-10 add another layer of complexity as shown in transplantations. Although IL-10 can stimulate the expansion of CD4⁺ and CD8⁺ T cells, leading to exacerbation of graft-versus-host disease in humanized mice (164), IL-10 can suppress allograft rejection in pancreatic islet transplantation when administered with rapamycin (165). Clinical challenges continue to hamper cytokine therapy, and IL-10 is no exception because of its wide range of producers and responders, a limitation to delineate the molecular mechanisms at specific cell types. More importantly, it is difficult to control cytokine actions because multiple cytokines can exert similar effects by displaying synergistic, agonistic, or antagonistic properties. However, when rIL-10 therapies have failed, other strategies were explored. For example, a cyclic adenosine monophosphate phosphodiesterase-4 inhibitor induces Bregs to produce IL-10 in patients with psoriasis and atopic dermatitis (166, 167). Such options may be better in patients if their ability to produce IL-10 remains intact. Likewise, naturally derived alternatives (e.g., curcumin) have been demonstrated to increase IL-10 production in the mouse models of bowel inflammation, pain, and allergies, among others (168). Such natural substitutes may have the potential to be translated for use in humans.

Conclusions

IL-10 is a multifunctional cytokine produced by multiple cell types. The innate immune cells, mainly macrophages, because of their inherent ability to rapidly respond to pathogens and initiate a broad range of cellular responses, have a higher capacity for producing cytokines than adaptive immune cells. This also may be true for tumors that are infiltrated with myeloid-derived suppressor cells (47). Conversely, adaptive immune cells (T cells and B cells) respond to pathogens Ag specifically, but the frequencies of Ag-specific lymphocytes range from 1 in 1×10^6 to 1×10^7 cells (169). Even with the expansion of their effector populations, as might occur to the largest proportion with CD8⁺ T cells ($\sim 10,000$ -fold) (170), not all T cells produce a set of cytokines in real-life situations. Although IL-10 was known to be secreted by both Th1 and Th2 cell types in humans (171), the identity of IL-10 as a Th2 cytokine is also lost in mice because Th1 cells can secrete IL-10 (172) in addition to various other Th subsets that are not discussed in this review [e.g., Th9, regulatory Tfh cells (173, 174)]. Nonetheless, functionalities of IL-10 have remained intact in both mice and humans, but no function can be singled out as unique to each species. Thus, observations made in mouse models may be translationally relevant, but outcomes should be viewed with caution, as noted with the failed PEG-IL-10 trials in cancer

patients described above. Furthermore, translation from animal models to clinical cancer trials in humans has been reported to be successful, with an average rate of $\sim 8\%$ (175). Therefore, setbacks are expected because efficacies of therapeutics are tested under highly defined conditions in experimental models involving inbred mouse strains as opposed to natural settings in the outbred human population.

Acknowledgments

We thank Dr. Scott McVey for critically reading this review and providing input.

Disclosures

The authors have no financial conflicts of interest.

References

- Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J. Immunol.* 136: 2348–2357.
- Cope, A., G. Le Friec, J. Cardone, and C. Kemper. 2011. The Th1 life cycle: molecular control of IFN- γ to IL-10 switching. *Trends Immunol.* 32: 278–286.
- Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J. Exp. Med.* 170: 2081–2095.
- Fernandez-Botran, R., V. M. Sanders, T. R. Mosmann, and E. S. Vitetta. 1988. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. *J. Exp. Med.* 168: 543–558.
- Fickenscher, H., S. Hör, H. Küpers, A. Knappe, S. Wittmann, and H. Sticht. 2002. The interleukin-10 family of cytokines. *Trends Immunol.* 23: 89–96.
- Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlusmeyer, T. E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat. Immunol.* 4: 63–68.
- Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. *J. Immunol.* 150: 353–360.
- Mestas, J., and C. C. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. *J. Immunol.* 172: 2731–2738.
- Ouyang, W., and A. O'Garra. 2019. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. *Immunity* 50: 871–891.
- Saraiva, M., P. Vieira, and A. O'Garra. 2020. Biology and therapeutic potential of interleukin-10. *J. Exp. Med.* 217: e20190418.
- Saraiva, M., and A. O'Garra. 2010. The regulation of IL-10 production by immune cells. *Nat. Rev. Immunol.* 10: 170–181.
- Moore, K. W., P. Vieira, D. F. Fiorentino, M. L. Trounstein, T. A. Khan, and T. R. Mosmann. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. *Science* 248: 1230–1234.
- Vieira, P., R. de Waal-Malefyt, M. N. Dang, K. E. Johnson, R. Kastelein, D. F. Fiorentino, J. E. deVries, M. G. Roncarolo, T. R. Mosmann, and K. W. Moore. 1991. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1. *Proc. Natl. Acad. Sci. USA* 88: 1172–1176.
- Kim, J. M., C. I. Brannan, N. G. Copeland, N. A. Jenkins, T. A. Khan, and K. W. Moore. 1992. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. *J. Immunol.* 148: 3618–3623.
- Windsor, W. T., R. Syto, A. Tsaropoulos, R. Zhang, J. Durkin, S. Baldwin, S. Paliwal, P. W. Mui, B. Pramanik, P. P. Trotta, et al. 1993. Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10. *Biochemistry* 32: 8807–8815.
- Minshawi, F., S. Lanvermann, E. McKenzie, R. Jeffery, K. Couper, S. Papoutsopoulou, A. Roers, and W. Muller. 2020. The generation of an engineered interleukin-10 protein with improved stability and biological function. *Front. Immunol.* 11: 1794.
- Josephson, K., R. DiGiacomo, S. R. Indelicato, A. H. Iyo, T. L. Nagabhusan, M. H. Parker, and M. R. Walter. 2000. Design and analysis of an engineered human interleukin-10 monomer. [Published erratum appears in 2000 *J. Biol. Chem.* 275: 25054.] *J. Biol. Chem.* 275: 13552–13557.
- Kurte, M., M. López, A. Aguirre, A. Escobar, J. C. Aguilón, J. Charo, C. G. Larsen, R. Kiessling, and F. Salazar-Onfray. 2004. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. *J. Immunol.* 173: 1731–1737.
- Kotenko, S. V., C. D. Krause, L. S. Izotova, B. P. Pollack, W. Wu, and S. Pestka. 1997. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. *EMBO J.* 16: 5894–5903.

20. Tan, J. C., S. R. Indelicato, S. K. Narula, P. J. Zavodny, and C. C. Chou. 1993. Characterization of interleukin-10 receptors on human and mouse cells. *J. Biol. Chem.* 268: 21053–21059.
21. Liu, Y., S. H. Wei, A. S. Ho, R. de Waal Malefyt, and K. W. Moore. 1994. Expression cloning and characterization of a human IL-10 receptor. *J. Immunol.* 152: 1821–1829.
22. Weber-Nordt, R. M., M. A. Meraz, and R. D. Schreiber. 1994. Lipopolysaccharide-dependent induction of IL-10 receptor expression on murine fibroblasts. *J. Immunol.* 153: 3734–3744.
23. Gibbs, V. C., and D. Pennica. 1997. CRF2-4: isolation of cDNA clones encoding the human and mouse proteins. *Gene* 186: 97–101.
24. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. *Annu. Rev. Immunol.* 19: 683–765.
25. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old cytokine. *Immunol. Rev.* 226: 205–218.
26. Wehinger, J., F. Gouilleux, B. Groner, J. Finke, R. Mertelmann, and R. M. Weber-Nordt. 1996. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. *FEBS Lett.* 394: 365–370.
27. Spencer, S. D., F. Di Marco, J. Hooley, S. Pitts-Meek, M. Bauer, A. M. Ryan, B. Sordat, V. C. Gibbs, and M. Aguet. 1998. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. *J. Exp. Med.* 187: 571–578.
28. Young, V. P., M. C. Mariano, C. C. Tu, K. M. Allaire, S. Avdic, B. Slobedman, and J. V. Spencer. 2017. Modulation of the host environment by human cytomegalovirus with viral interleukin 10 in peripheral blood. *J. Infect. Dis.* 215: 874–882.
29. Jog, N. R., E. F. Chakravarty, J. M. Guthridge, and J. A. James. 2018. Epstein barr virus interleukin 10 suppresses anti-inflammatory phenotype in human monocytes. *Front. Immunol.* 9: 2198.
30. Fleming, S. B., C. A. McCaughan, A. E. Andrews, A. D. Nash, and A. A. Mercer. 1997. A homolog of interleukin-10 is encoded by the poxvirus orf virus. *J. Virol.* 71: 4857–4861.
31. Avdic, S., B. P. McSharry, M. Steain, E. Poole, J. Sinclair, A. Abendroth, and B. Slobedman. 2016. Human cytomegalovirus-encoded human interleukin-10 (IL-10) homolog amplifies its immunomodulatory potential by upregulating human IL-10 in monocytes. *J. Virol.* 90: 3819–3827.
32. Liu, Y., R. de Waal Malefyt, F. Briere, C. Parham, J. M. Bridon, J. Banchereau, K. W. Moore, and J. Xu. 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. *J. Immunol.* 158: 604–613.
33. Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. *Annu. Rev. Immunol.* 11: 165–190.
34. Kedzierski, L., and K. J. Evans. 2014. Immune responses during cutaneous and visceral leishmaniasis. *Parasitology* 30: 1–19.
35. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to *Leishmania major*. *Science* 257: 539–542.
36. Hailu, A., J. N. Menon, N. Berhe, L. Gedamu, T. H. Hassard, P. A. Kager, J. Olobo, and P. A. Bretscher. 2001. Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. *J. Infect. Dis.* 184: 112–115.
37. Herrero, C., X. Hu, W. P. Li, S. Samuels, M. N. Sharif, S. Kotenko, and L. B. Ivshin. 2003. Reprogramming of IL-10 activity and signaling by IFN-gamma. *J. Immunol.* 171: 5034–5041.
38. Snapper, C. M., F. D. Finkelman, and W. E. Paul. 1988. Regulation of IgG1 and IgE production by interleukin 4. *Immunol. Rev.* 102: 51–75.
39. Kouro, T., and K. Takatsu. 2009. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. *Int. Immunol.* 21: 1303–1309.
40. McKenzie, G. J., A. Bancroft, R. K. Grencis, and A. N. McKenzie. 1998. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. *Curr. Biol.* 8: 339–342.
41. Bednarz-Misa, I., D. Diakowska, I. Szczuka, P. Fortuna, A. Kubiak, J. Rosińczuk, and M. Krzystek-Korpacka. 2020. Interleukins 4 and 13 and their receptors are differently expressed in gastrointestinal tract cancers, depending on the anatomical site and disease advancement, and improve colon cancer cell viability and motility. *Cancers (Basel)* 12:1463.
42. Hummelshoj, L., L. P. Ryder, and L. K. Poulsen. 2006. The role of the interleukin-10 subfamily members in immunoglobulin production by human B cells. *Scand. J. Immunol.* 64: 40–47.
43. Levy, Y., and J. C. Brouet. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. *J. Clin. Invest.* 93: 424–428.
44. Larson, D., M. P. Hübner, M. N. Torrero, C. P. Morris, A. Brankin, B. E. Swierczewski, S. J. Davies, B. M. Vonakis, and E. Mitre. 2012. Chronic helminth infection reduces basophil responsiveness in an IL-10-dependent manner. *J. Immunol.* 188: 4188–4199.
45. Dooley, A., M. Quintana, M. Cheung, L. L. Sun, and N. Gupta. 2018. The B cell IL-10 receptor suppresses antibody production. *J. Immunol.* 200: 164.9.
46. Madan, R., F. Demircik, S. Surianarayanan, J. L. Allen, S. Divanovic, A. Trompette, N. Yoge, Y. Gu, M. Khodoun, D. Hildeman, et al. 2009. Nonredundant roles for B cell-derived IL-10 in immune counter-regulation. *J. Immunol.* 183: 2312–2320.
47. Hart, K. M., K. T. Byrne, M. J. Molloy, E. M. Usherwood, and B. Berwin. 2011. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. *Front. Immunol.* 2: 29.
48. Bouabe, H., Y. Liu, M. Moser, M. R. Bösl, and J. Heesemann. 2011. Novel highly sensitive IL-10-beta-lactamase reporter mouse reveals cells of the innate immune system as a substantial source of IL-10 in vivo. *J. Immunol.* 187: 3165–3176.
49. Facciotti, F., P. Larghi, R. Bosotti, C. Vasco, N. Gagliani, C. Cordiglieri, S. Mazzara, V. Ranzani, E. Rottoli, S. Curri, et al. 2020. Evidence for a pathogenic role of extra-follicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus. *Proc. Natl. Acad. Sci. USA* 117: 7305–7316.
50. Kamanaka, M., S. T. Kim, Y. Y. Wan, F. S. Sutterwala, M. Lara-Tejero, J. E. Galán, E. Harhaj, and R. A. Flavell. 2006. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. *Immunity* 25: 941–952.
51. Ostmann, A., H. J. Paust, U. Panzer, C. Wegscheid, S. Kapffer, S. Huber, R. A. Flavell, A. Erhardt, and G. Tiegs. 2013. Regulatory T cell-derived IL-10 ameliorates crescentic GN. *J. Am. Soc. Nephrol.* 24: 930–942.
52. Motomura, Y., H. Kitamura, A. Hijikata, Y. Matsunaga, K. Matsumoto, H. Inoue, K. Atarashi, S. Hori, H. Watarai, J. Zhu, et al. 2011. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. *Nat. Immunol.* 12: 450–459.
53. Zhang, H., and V. Kuchroo. 2019. Epigenetic and transcriptional mechanisms for the regulation of IL-10. *Semin. Immunol.* 44: 101324.
54. Messi, M., I. Giacchetto, K. Nagata, A. Lanzavecchia, G. Natoli, and F. Sallusto. 2003. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. *Nat. Immunol.* 4: 78–86.
55. Ouyang, W., S. H. Ranganath, K. Weindel, D. Bhattacharya, T. L. Murphy, W. C. Sha, and K. M. Murphy. 1998. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. *Immunity* 9: 745–755.
56. Zhu, C., K. Sakuishi, S. Xiao, Z. Sun, S. Zaghouani, G. Gu, C. Wang, D. J. Tan, C. Wu, M. Rangachari, et al. 2015. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. [Published erratum appears in 2015 *Nat. Commun.* 6: 7657.] *Nat. Commun.* 6: 6072.
57. Wang, C., N. Yosef, J. Gaublotte, C. Wu, Y. Lee, C. B. Clish, J. Kaminski, S. Xiao, G. Meyer Zu Horste, M. Pawlak, et al. 2015. CD5LAIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. *Cell* 163: 1413–1427.
58. Wu, X., J. Tian, and S. Wang. 2018. Insight into non-pathogenic Th17 cells in autoimmune diseases. *Front. Immunol.* 9: 1112.
59. Eyerich, S., K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, F. Cianfrani, T. Odoriso, C. Traidl-Hoffmann, H. Behrendt, et al. 2009. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J. Clin. Invest.* 119: 3573–3585.
60. Sun, J., R. Madan, C. L. Karp, and T. J. Braciale. 2009. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. *Nat. Med.* 15: 277–284.
61. Jankovic, D., M. C. Kullberg, C. G. Feng, R. S. Goldszmid, C. M. Collazo, M. Wilson, T. A. Wynn, M. Kamanaka, R. A. Flavell, and A. Sher. 2007. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. *J. Exp. Med.* 204: 273–283.
62. Anderson, C. F., M. Oukka, V. J. Kuchroo, and D. Sacks. 2007. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. *J. Exp. Med.* 204: 285–297.
63. Chatelain, R., S. Mauze, and R. L. Coffman. 1999. Experimental *Leishmania major* infection in mice: role of IL-10. *Parasite Immunol.* 21: 211–218.
64. van der Vlugt, L. E., L. A. Labuda, A. Ozir-Fazalikhani, E. Lievers, A. K. Gloudemans, K. Y. Liu, T. A. Barr, T. Sparwasser, L. Boon, U. A. Ngoa, et al. 2012. Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. *PLoS One* 7: e30883.
65. Rong, H. M., T. Li, C. Zhang, D. Wang, Y. Hu, K. Zhai, H. Z. Shi, and Z. H. Tong. 2019. IL-10-producing B cells regulate Th1/Th17-cell immune responses in *Pneumocystis pneumonia*. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 316: L291–L301.
66. Ronet, C., Y. Hauyon-La Torre, M. Revaz-Breton, B. Mastelic, F. Tacchini-Cottier, J. Louis, and P. Launois. 2010. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with *Leishmania major* through IL-10 production. *J. Immunol.* 184: 886–894.
67. Matsumoto, M., A. Baba, T. Yokota, H. Nishikawa, Y. Ohkawa, H. Kayama, A. Kallies, S. L. Nutt, S. Sakaguchi, K. Takeda, et al. 2014. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. *Immunity* 41: 1040–1051.
68. Xin, G., R. Zander, D. M. Schauder, Y. Chen, J. S. Weinstein, W. R. Drobyski, V. Tarakanova, J. Craft, and W. Cui. 2018. Single-cell RNA sequencing unveils an IL-10-producing helper subset that sustains humoral immunity during persistent infection. *Nat. Commun.* 9: 5037.
69. Cañete, P. F., R. A. Sweet, P. Gonzalez-Figueroa, I. Papa, N. Ohkura, H. Bolton, J. A. Roco, M. Cuenca, K. J. Bassett, I. Sayin, et al. 2019. Regulatory roles of IL-10-producing human follicular T cells. *J. Exp. Med.* 216: 1843–1856.
70. Csóka, B., Z. H. Németh, L. Virág, P. Gergely, S. J. Leibovich, P. Pacher, C. X. Sun, M. R. Blackburn, E. S. Vizi, E. A. Deitch, and G. Haskó. 2007. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to *Escherichia coli*. *Blood* 110: 2685–2695.
71. Luo, Y., R. Han, D. P. Evanoff, and X. Chen. 2010. Interleukin-10 inhibits *Mycobacterium bovis* bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. *Clin. Exp. Immunol.* 160: 359–368.
72. O'Garra, A., P. L. Vieira, P. Vieira, and A. E. Goldfeld. 2004. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. *J. Clin. Invest.* 114: 1372–1378.
73. Lim, J. Y., K. I. Im, E. S. Lee, N. Kim, Y. S. Nam, Y. W. Jeon, and S. G. Cho. 2016. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. *Sci. Rep.* 6: 26851.

74. Nidetz, N. F., M. C. McGee, C. B. Limper, K. X. Ye, R. Islam, A. August, and W. S. Huang. 2020. Development of regulatory IL-10-producing ILCs during type 2 inflammation. *J. Immunol.* 204: 154–4.
75. Doetze, A., J. Satoguina, G. Burchard, T. Rau, C. Löliger, B. Fleischer, and A. Hoerauf. 2000. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. *Int. Immunol.* 12: 623–630.
76. Chanteux, H., A. C. Guisset, C. Pilette, and Y. Sibille. 2007. LPS induces IL-10 production by human alveolar macrophages via MAPKs- and Sp1-dependent mechanisms. *Respir. Res.* 8: 71.
77. Salez, L., M. Singer, V. Balloy, C. Créminon, and M. Chignard. 2000. Lack of IL-10 synthesis by murine alveolar macrophages upon lipopolysaccharide exposure. Comparison with peritoneal macrophages. *J. Leukoc. Biol.* 67: 545–552.
78. Davey, M. S., N. Tamassia, M. Rossato, F. Bazzoni, F. Calzetti, K. Bruderek, M. Sironi, L. Zimmer, B. Bottazzi, A. Mantovani, et al. 2011. Failure to detect production of IL-10 by activated human neutrophils. *Nat. Immunol.* 12: 1017–1018, author reply 1018–1020.
79. Tamassia, N., F. Bianchetto-Aguilera, F. Arruda-Silva, E. Gardiman, S. Gasperini, F. Calzetti, and M. A. Cassatella. 2018. Cytokine production by human neutrophils: revisiting the “dark side of the moon”. *Eur. J. Clin. Invest.* 48(Suppl 2): e12952.
80. Lewkowicz, N., M. P. Mycko, P. Przygodzka, H. Ćwiklińska, M. Cichalewska, M. Matysiak, K. Selmaj, and P. Lewkowicz. 2016. Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10. *Mucosal Immunol.* 9: 364–378.
81. Jerkic, M., C. Masterson, L. Ormesher, S. Gagnon, S. Goyal, R. Rabani, G. Otulakowski, H. Zhang, B. P. Kavanagh, and J. G. Laffey. 2019. Overexpression of IL-10 enhances the efficacy of human umbilical-cord-derived mesenchymal stromal cells in *E. coli* pneumosepsis. *J. Clin. Med.* 8: 847.
82. Wang, J., H. Ren, X. Yuan, H. Ma, X. Shi, and Y. Ding. 2018. Interleukin-10 secreted by mesenchymal stem cells attenuates acute liver failure through inhibiting pyroptosis. *Hepatal. Res.* 48: E194–E202.
83. Hyun, J., L. Romero, R. Riveron, C. Flores, S. Kanagavelu, K. D. Chung, A. Alonso, J. Sorolongo, J. Ruiz, A. Manukyan, et al. 2015. Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk. *J. Innate Immun.* 7: 87–101.
84. Hokenson, M. A., Y. Wang, R. L. Hawwa, Z. Huang, S. Sharma, and J. Sanchez-Esteban. 2013. Reduced IL-10 production in fetal type II epithelial cells exposed to mechanical stretch is mediated via activation of IL-6-SOCS3 signaling pathway. *PLoS One* 8: e59598.
85. Gastl, G. A., J. S. Abrams, D. M. Nanus, R. Oosterkamp, J. Silver, F. Liu, M. Chen, A. P. Albino, and N. H. Bander. 1993. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. *Int. J. Cancer* 55: 96–101.
86. O’Garra, A., G. Stapleton, V. Dhar, M. Pearce, J. Schumacher, H. Rugo, D. Barbis, A. Stall, J. Cupp, K. Moore, et al. 1990. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. *Int. Immunol.* 2: 821–832.
87. Byun, J. S., Y. G. Suh, H. S. Yi, Y. S. Lee, and W. I. Jeong. 2013. Activation of toll-like receptor 3 attenuates alcoholic liver injury by stimulating Kupffer cells and stellate cells to produce interleukin-10 in mice. *J. Hepatol.* 58: 342–349.
88. Lee, Y. S., A. Amadi-Obi, C. R. Yu, and C. E. Egwuagu. 2011. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. *Immunology* 132: 492–502.
89. Feng, P., J. Chai, M. Zhou, N. Simon, L. Huang, and H. Wang. 2014. Interleukin-10 is produced by a specific subset of taste receptor cells and critical for maintaining structural integrity of mouse taste buds. *J. Neurosci.* 34: 2689–2701.
90. Meunier, N., L. Briand, A. Jacquin-Piques, L. Brondel, and L. Pénicaud. 2021. COVID 19-induced smell and taste impairments: putative impact on physiology. *Front. Physiol.* 11: 625110.
91. Zhao, Y., L. Qin, P. Zhang, K. Li, L. Liang, J. Sun, B. Xu, Y. Dai, X. Li, C. Zhang, et al. 2020. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. *JCI Insight* 5: 139834.
92. Song, P., W. Li, J. Xie, Y. Hou, and C. You. 2020. Cytokine storm induced by SARS-CoV-2. *Clin. Chim. Acta* 509: 280–287.
93. Lu, L., H. Zhang, D. J. Dauphars, and Y. W. He. 2021. A potential role of interleukin 10 in COVID-19 pathogenesis. *Trends Immunol.* 42: 3–5.
94. Islam, H., T. C. Chamberlain, A. L. Mui, and J. P. Little. 2021. Elevated interleukin-10 levels in COVID-19: potentiation of pro-inflammatory responses or impaired anti-inflammatory action? *Front. Immunol.* 12: 677008.
95. Couper, K. N., D. G. Blount, and E. M. Riley. 2008. IL-10: the master regulator of immunity to infection. *J. Immunol.* 180: 5771–5777.
96. Chang, C. H., M. Furue, and K. Tamaki. 1995. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. *Eur. J. Immunol.* 25: 394–398.
97. Willems, F., A. Marchant, J. P. Delville, C. Gérard, A. Delvaux, T. Velu, M. de Boer, and M. Goldman. 1994. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. *Eur. J. Immunol.* 24: 1007–1009.
98. Atri, C., F. Z. Guerfali, and D. Laouini. 2018. Role of human macrophage polarization in inflammation during infectious diseases. *Int. J. Mol. Sci.* 19: 1801.
99. von Hachling, S., K. Wolk, C. Höflich, S. Kunz, B. H. Grünberg, W. D. Döcke, U. Reineke, K. Asadullah, W. Sterry, H. D. Volk, and R. Sabat. 2015. Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10’s inhibitory mechanisms. [Published erratum appears in 2015 *Genes Immun.* 16: 366.] *Genes Immun.* 16: 8–14.
100. Pino-Martínez, A. M., C. G. Miranda, E. I. Batalla, S. M. González-Cappa, and C. D. Alba Soto. 2019. IL-10 participates in the expansion and functional activation of CD8⁺ T cells during acute infection with *Trypanosoma cruzi*. *J. Leukoc. Biol.* 105: 163–175.
101. Sasaki, H., Y. Okamoto, T. Kawai, R. Kent, M. Taubman, and P. Stashenko. 2004. The interleukin-10 knockout mouse is highly susceptible to *Porphyromonas gingivalis*-induced alveolar bone loss. *J. Periodontol.* 35: 432–441.
102. Haben, L., W. Hartmann, S. Specht, A. Hoerauf, A. Roers, W. Müller, and M. Breloer. 2013. T-cell-derived, but not B-cell-derived, IL-10 suppresses antigen-specific T-cell responses in *Litomosoides sigmodontis*-infected mice. *Eur. J. Immunol.* 43: 1799–1805.
103. Schopf, L. R., K. F. Hoffmann, A. W. Cheever, J. F. Urban, Jr., and T. A. Wynn. 2002. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. *J. Immunol.* 168: 2383–2392.
104. Schwarz, T., K. A. Remer, W. Nahrendorf, A. Masic, L. Siewe, W. Müller, A. Roers, and H. Moll. 2013. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. *PLoS Pathog.* 9: e1003476.
105. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to *Leishmania donovani* infection. *Eur. J. Immunol.* 31: 2848–2856.
106. Redford, P. S., A. Boonstra, S. Read, J. Pitt, C. Graham, E. Stavropoulos, G. J. Bancroft, and A. O’Garra. 2010. Enhanced protection to *Mycobacterium tuberculosis* infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. *Eur. J. Immunol.* 40: 2200–2210.
107. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. *J. Immunol.* 166: 1141–1147.
108. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4⁺CD25⁺ regulatory T cells control *Leishmania major* persistence and immunity. *Nature* 420: 502–507.
109. Beebe, A. M., D. J. Cua, and R. de Waal Malefyt. 2002. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). *Cytokine Growth Factor Rev.* 13: 403–412.
110. Glocker, E. O., D. Kotlarz, C. Klein, N. Shah, and B. Grimbacher. 2011. IL-10 and IL-10 receptor defects in humans. *Ann. N. Y. Acad. Sci.* 1246: 102–107.
111. Iyer, S. S., and G. Cheng. 2012. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. *Crit. Rev. Immunol.* 32: 23–63.
112. Eskdale, J., G. Gallagher, C. L. Verweij, V. Keijsers, R. G. Westendorp, and T. W. Huizinga. 1998. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. *Proc. Natl. Acad. Sci. USA* 95: 9465–9470.
113. Yang, S. L., and S. J. Huang. 2019. Interleukin-10 polymorphisms (rs1800871, rs1800872, and rs1800896) and periodontitis risk: A meta-analysis. *Arch. Oral Biol.* 97: 59–66.
114. Gao, J., L. Wei, R. Fu, J. Wei, D. Niu, L. Wang, H. Ge, Q. Yu, M. Wang, X. Liu, and W. Zhang. 2017. Association of interleukin-10 polymorphisms (rs1800872, rs1800871, and rs1800896) with predisposition to IgA nephropathy in a Chinese Han population: a case-control study. *Kidney Blood Press. Res.* 42: 89–98.
115. Holster, A., K. Nuolivirta, S. Törmänen, E. Lauhkonen, J. Teräsjarvi, J. Vuononvirta, P. Koponen, M. Helminen, Q. He, and M. Korppi. 2019. Interleukin-10 gene polymorphism rs1800896 is associated with post-bronchiolitis asthma at 11–13 years of age. *Acta Paediatr.* 108: 2064–2069.
116. Zhu, X., C. Hou, M. Tu, C. Shi, L. Yin, Y. Peng, Q. Li, and Y. Miao. 2019. Gene polymorphisms in the interleukins gene and the risk of acute pancreatitis: A meta-analysis. *Cytokine* 115: 50–59.
117. Su, Y., and H. Zhao. 2020. Predisposition of inflammatory bowel disease is influenced by IL-8, IL-10, and IL-18 polymorphisms: a meta-analysis. *Int. Arch. Allergy Immunol.* 181: 799–806.
118. Yuan, Y., X. Wang, L. Ren, Y. Kong, J. Bai, and Y. Yan. 2019. Associations between interleukin-10 gene polymorphisms and systemic lupus erythematosus risk: a meta-analysis with trial sequential analysis. *Clin. Exp. Rheumatol.* 37: 242–253.
119. Moens, L., and S. G. Tangye. 2014. Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. *Front. Immunol.* 5: 65.
120. Yoon, S. O., X. Zhang, P. Berner, and Y. S. Choi. 2009. IL-21 and IL-10 have redundant roles but differential capacities at different stages of Plasma Cell generation from human Germinal Center B cells. *J. Leukoc. Biol.* 86: 1311–1318.
121. Leach, M. W., N. J. Davidson, M. M. Fort, F. Powrie, and D. M. Rennick. 1999. The role of IL-10 in inflammatory bowel disease: “of mice and men”. *Toxicol. Pathol.* 27: 123–133.
122. Llorente, L., Y. Richaud-Patin, J. Wijdenes, J. Alcocer-Varela, M. C. Maillor, I. Durand-Gasselin, B. M. Fourrier, P. Galanaud, and D. Emilie. 1993. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. *Eur. Cytokine Netw.* 4: 421–427.
123. Facciotti, F., P. Larghi, R. Bosotti, C. Vasco, N. Gagliani, C. Cordiglieri, S. Mazzara, V. Ranzani, E. Rotoli, S. Curti, et al. 2020. Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6⁺B helper T cells in systemic lupus erythematosus. *Proc. Natl. Acad. Sci. USA* 117: 7305–7316.
124. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. *J. Exp. Med.* 179: 305–310.
125. Godsell, J., I. Rudloff, R. Kandane-Rathnayake, A. Hoi, M. F. Nold, E. F. Morand, and J. Harris. 2016. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. *Sci. Rep.* 6: 34604.

126. Ostlie, N. S., P. I. Karachunski, W. Wang, C. Monfardini, M. Kronenberg, and B. M. Conti-Fine. 2001. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. *J. Immunol.* 166: 4853–4862.
127. Wilson, M. S., E. Elnekave, M. M. Mentink-Kane, M. G. Hodges, J. T. Pesce, T. R. Ramalingam, R. W. Thompson, M. Kamanaka, R. A. Flavell, A. Keane-Myers, et al. 2007. IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. *J. Clin. Invest.* 117: 2941–2951.
128. Grünig, G., D. B. Corry, M. W. Leach, B. W. Seymour, V. P. Kurup, and D. M. Rennick. 1997. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. *J. Exp. Med.* 185: 1089–1099.
129. Lim, S., E. Crawley, P. Woo, and P. J. Barnes. 1998. Haplotype associated with low interleukin-10 production in patients with severe asthma. *Lancet* 352: 113.
130. Coomes, S. M., Y. Kannan, V. S. Pelly, L. J. Entwistle, R. Guidi, J. Perez-Lloret, N. Nikolov, W. Müller, and M. S. Wilson. 2017. CD4⁺ Th2 cells are directly regulated by IL-10 during allergic airway inflammation. *Mucosal Immunol.* 10: 150–161.
131. Akuffo, H. O., T. E. Fehniger, and S. Britton. 1988. Differential recognition of *Leishmania* aethiopia antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. *J. Immunol.* 141: 2461–2466.
132. Polukort, S. H., J. Rovatti, L. Carlson, C. Thompson, J. Ser-Dolansky, S. R. Kinney, S. S. Schneider, and C. B. Mathias. 2016. IL-10 enhances IgE-mediated mast cell responses and is essential for the development of experimental food allergy in IL-10-deficient mice. *J. Immunol.* 196: 4865–4876.
133. Uyemura, K., L. L. Demer, S. C. Castle, D. Jullien, J. A. Berliner, M. K. Gately, R. R. Warrier, N. Pham, A. M. Fogelman, and R. L. Modlin. 1996. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. *J. Clin. Invest.* 97: 2130–2138.
134. Potteaux, S., B. Esposito, O. van Oostrom, V. Brun, P. Ardouin, H. Groux, A. Tedgui, and Z. Mallat. 2004. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. *Arterioscler. Thromb. Vasc. Biol.* 24: 1474–1478.
135. Jung, M., Y. Ma, R. P. Iyer, K. Y. DeLeon-Pennell, A. Yabluchanskiy, M. R. Garrett, and M. L. Lindsey. 2017. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. *Basic Res. Cardiol.* 112: 33.
136. Kim, H. J., T. Higashimori, S. Y. Park, H. Choi, J. Dong, Y. J. Kim, H. L. Noh, Y. R. Cho, G. Cline, W. B. Kim, and J. K. Kim. 2004. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. *Diabetes* 53: 1060–1067.
137. Scarpelli, D., M. Cardellini, F. Andreozzi, E. Laratta, M. L. Hribal, M. A. Marini, V. Tassi, R. Lauro, F. Perticone, and G. Sesti. 2006. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. *Diabetes* 55: 1529–1533.
138. Thaxton, J. E., and S. Sharma. 2010. Interleukin-10: a multi-faceted agent of pregnancy. *Am. J. Reprod. Immunol.* 63: 482–491.
139. Kalkunte, S., T. Nevers, W. E. Norris, and S. Sharma. 2011. Vascular IL-10: a protective role in preeclampsia. *J. Reprod. Immunol.* 88: 165–169.
140. Espino Y Sosa, S., A. Flores-Pliego, A. Espejel-Núñez, D. Medina-Bastidas, F. Vadillo-Ortega, V. Zaga-Clavellina, and G. Estrada-Gutierrez. 2017. New insights into the role of matrix metalloproteinases in preeclampsia. *Int. J. Mol. Sci.* 18: 1448.
141. Shouval, D. S., J. Ouahed, A. Biswas, J. A. Goettel, B. H. Horwitz, C. Klein, A. M. Muise, and S. B. Snapper. 2014. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. *Adv. Immunol.* 122: 177–210.
142. Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, and W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75: 263–274.
143. Keubler, L. M., M. Buettner, C. Häger, and A. Bleich. 2015. A multihit model: colitis lessons from the interleukin-10-deficient mouse. *Inflamm. Bowel Dis.* 21: 1967–1975.
144. Colombel, J. F., P. Rutgeerts, H. Malchow, M. Jacyna, O. H. Nielsen, J. Rask-Madsen, S. Van Deventer, A. Ferguson, P. Desreumaux, A. Forbes, et al. 2001. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. *Gut* 49: 42–46.
145. Schwager, K., M. Kaspar, F. Bantz, R. Marcolongo, E. Paresce, D. Neri, and E. Trachsel. 2009. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. *Arthritis Res. Ther.* 11: R142.
146. Bernstein, C. N. 2017. Review article: changes in the epidemiology of inflammatory bowel disease—clues for aetiology. *Aliment. Pharmacol. Ther.* 46: 911–919.
147. Sato, T., P. McCue, K. Masuoka, S. Salwen, E. C. Lattime, M. J. Mastrangelo, and D. Berd. 1996. Interleukin-10 production by human melanoma. *Clin. Cancer Res.* 2: 1383–1390.
148. Giovarelli, M., P. Musiani, A. Modesti, P. Dellabona, G. Casorati, A. Allione, M. Consalvo, F. Cavallo, F. di Piero, C. De Giovanni, et al. 1995. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. *J. Immunol.* 155: 3112–3123.
149. Guo, Y., Y. Q. Xie, M. Gao, Y. Zhao, F. Franco, M. Wenes, I. Siddiqui, A. Bevilacqua, H. Wang, H. Yang, et al. 2021. Metabolic reprogramming of terminally exhausted CD8⁺ T cells by IL-10 enhances anti-tumor immunity. *Nat. Immunol.* 22: 746–756.
150. Mumm, J. B., J. Emmerich, X. Zhang, I. Chan, L. Wu, S. Mauze, S. Blaisdell, B. Basham, J. Dai, J. Grein, et al. 2011. IL-10 elicits IFN γ -dependent tumor immune surveillance. *Cancer Cell* 20: 781–796.
151. Chan, I. H., D. Van Hoof, M. Abramova, M. Bilardello, E. Mar, B. Jorgensen, S. McCauley, H. Bal, M. Ofi, P. Van Vlasselaer, and J. B. Mumm. 2016. PEGylated IL-10 activates Kupffer cells to control hypercholesterolemia. *PLoS One* 11: e0156229.
152. Naing, A., J. R. Infante, K. P. Papadopoulos, I. H. Chan, C. Shen, N. P. Ratti, B. Rojo, K. A. Autio, D. J. Wong, M. R. Patel, et al. 2018. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8⁺ T cell invigoration and polyclonal T cell expansion in cancer patients. *Cancer Cell* 34: 775–791.e3.
153. Autio, K., and M. Ofi. 2019. Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics. *Curr. Oncol. Rep.* 21: 19.
154. Hecht, J. R., S. Lonardi, J. Bendell, H. W. Sim, T. Macarulla, C. D. Lopez, E. Van Cutsem, A. J. Muñoz Martín, J. O. Park, R. Greil, et al. 2021. Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA). *J. Clin. Oncol.* 39: 1108–1118.
155. Spiegel, D., R. Jotte, J. Nemunaitis, M. Shum, J. Schneider, J. Goldschmidt, J. Eisenstein, D. Berz, L. Seneviratne, M. Socotanu, et al. 2021. Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2). *J. Thorac. Oncol.* 16: 327–333.
156. Naing, A., D. J. Wong, J. R. Infante, W. M. Korn, R. Aljumaily, K. P. Papadopoulos, K. A. Autio, S. Pant, T. M. Bauer, A. Drakaki, et al. 2019. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. *Lancet Oncol.* 20: 1544–1555.
157. Rojas, J. M., M. Avia, V. Martín, and N. Sevilla. 2017. IL-10: a multifunctional cytokine in viral infections. *J. Immunol. Res.* 2017: 6104054.
158. Laidlaw, B. J., W. Cui, R. A. Amezcua, S. M. Gray, T. Guan, Y. Lu, Y. Kobayashi, R. A. Flavell, S. H. Kleinstein, J. Craft, and S. M. Kaech. 2015. Production of IL-10 by CD4⁺ regulatory T cells during the resolution of infection promotes the maturation of memory CD8⁺ T cells. *Nat. Immunol.* 16: 871–879.
159. Stacey, M. A., M. Marsden, E. C. Wang, G. W. Wilkinson, and I. R. Humphreys. 2011. IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection. *J. Immunol.* 187: 2944–2952.
160. Trandem, K., J. Zhao, E. Fleming, and S. Perlman. 2011. Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. *J. Immunol.* 186: 3642–3652.
161. De Maria, A., M. Fogli, S. Mazza, M. Basso, A. Picciotto, P. Costa, S. Congia, M. C. Mingari, and L. Moretta. 2007. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. *Eur. J. Immunol.* 37: 445–455.
162. Marlow, G. J., D. van Gent, and L. R. Ferguson. 2013. Why interleukin-10 supplementation does not work in Crohn's disease patients. *World J. Gastroenterol.* 19: 3931–3941.
163. Li, M. C., and S. H. He. 2004. IL-10 and its related cytokines for treatment of inflammatory bowel disease. *World J. Gastroenterol.* 10: 620–625.
164. Abraham, S., J. G. Choi, C. Ye, N. Manjunath, and P. Shankar. 2015. IL-10 exacerbates xenogenic GVHD by inducing massive human T cell expansion. *Clin. Immunol.* 156: 58–64.
165. Battaglia, M., A. Stabilini, E. Draghici, S. Gregori, C. Mocchetti, E. Bonifacio, and M. G. Roncarolo. 2006. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. *Diabetes* 55: 40–49.
166. Mavropoulos, A., E. Zafiriou, T. Simopoulou, A. G. Brotis, C. Laskos, A. Roussaki-Schulze, C. G. Katsiari, D. P. Bogdanos, and L. I. Sakkas. 2019. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. *Rheumatology (Oxford)* 58: 2240–2250.
167. Saporito, R. C., and D. J. Cohen. 2016. A prenilast use for moderate-to-severe atopic dermatitis in pediatric patients. *Case Rep. Dermatol.* 8: 179–184.
168. Mollazadeh, H., A. F. G. Cicero, C. N. Blesso, M. Pirro, M. Majeed, and A. Sahebkar. 2019. Immune modulation by curcumin: The role of interleukin-10. *Crit. Rev. Food Sci. Nutr.* 59: 89–101.
169. Alanio, C., F. Lemaitre, H. K. Law, M. Hasan, and M. L. Albert. 2010. Enumeration of human antigen-specific naive CD8⁺ T cells reveals conserved precursor frequencies. *Blood* 115: 3718–3725.
170. Cui, W., and S. M. Kaech. 2010. Generation of effector CD8⁺ T cells and their conversion to memory T cells. *Immunol. Rev.* 236: 151–166.
171. Yssel, H., R. De Waal Malefyt, M. G. Roncarolo, J. S. Abrams, R. Lahesmaa, H. Spits, and J. E. de Vries. 1992. IL-10 is produced by subsets of human CD4⁺ T cell clones and peripheral blood T cells. *J. Immunol.* 149: 2378–2384.
172. Trinchieri, G. 2007. Interleukin-10 production by effector T cells: Th1 cells show self control. *J. Exp. Med.* 204: 239–243.
173. Jäger, A., V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. *J. Immunol.* 183: 7169–7177.
174. Laidlaw, B. J., Y. Lu, R. A. Amezcua, J. S. Weinstein, J. A. Vander Heiden, N. T. Gupta, S. H. Kleinstein, S. M. Kaech, and J. Craft. 2017. Interleukin-10 from CD4⁺ follicular regulatory T cells promotes the germinal center response. *Sci. Immunol.* 2: eaan4767.
175. Mak, I. W., N. Evaniew, and M. Ghert. 2014. Lost in translation: animal models and clinical trials in cancer treatment. *Am. J. Transl. Res.* 6: 114–118.